Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tharimmune Inc THAR

Healthcare Biotechnology
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active... see more

Recent & Breaking News (NDAQ:THAR)

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Accesswire November 18, 2024

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Accesswire November 13, 2024

Tharimmune Announces Upcoming Conference Presentations

Accesswire November 4, 2024

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Accesswire October 30, 2024

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Accesswire October 28, 2024

Tharimmune Announces Upcoming Conference Presentations

Accesswire October 25, 2024

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Accesswire September 30, 2024

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Accesswire September 16, 2024

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Accesswire July 22, 2024

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Accesswire July 17, 2024

Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104

Accesswire July 16, 2024

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

Accesswire July 10, 2024

Tharimmune Announces $2.08 Million Private Placement

Accesswire June 20, 2024

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Accesswire June 17, 2024

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Accesswire June 10, 2024

Tharimmune to Present at 2024 BIO International Convention

Accesswire May 29, 2024

Tharimmune Announces 1-for-15 Reverse Stock Split

Accesswire May 22, 2024

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Accesswire April 30, 2024

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Accesswire April 23, 2024

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Accesswire April 15, 2024